Fosfomycine

Fosfomycin tromethamine

Usages autorisés

• Fosfomycin tromethamine granules for oral solution is indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis.
• If persistence or reappearance of bacteriuria occurs after treatment with fosfomycin tromethamine granules for oral solution, other therapeutic agents should be selected (see PRECAUTIONS and CLINICAL STUDIES sections).
• Fosfomycin tromethamine granules for oral solution is not indicated for the treatment of pyelonephritis or perinephric abscess.

Formes et dosages

• Fosfomycin Tromethamine Granules for Oral Solution is supplied as a white to off-white powder in a single-dose sachet containing the equivalent of 3 grams of fosfomycin.

Comment il se prend

• The recommended dosage for women 18 years of age and older for uncomplicated urinary tract infection (acute cystitis) is one sachet of fosfomycin tromethamine granules for oral solution.
• Fosfomycin tromethamine granules for oral solution may be taken with or without food.
• Fosfomycin tromethamine granules for oral solution should not be taken in its dry form.
• Always mix fosfomycin tromethamine granules for oral solution with water before ingesting (see PREPARATION section).

Ne doit pas être utilisé en cas de

• Fosfomycin tromethamine granules for oral solution is contraindicated in patients with known hypersensitivity to the drug.

Interactions

• Metoclopramide When co-administered with fosfomycin tromethamine, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.
• Other drugs that increase gastrointestinal motility may produce similar effects.
• Cimetidine Cimetidine does not affect the pharmacokinetics of fosfomycin when co-administered with fosfomycin tromethamine.

Mises en garde et précautions

• Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including fosfomycin tromethamine, and may range in severity from mild diarrhea to fatal colitis.
• Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.
• C. difficile produces toxins A and B which contribute to the development of CDAD.
• Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.

Effets indésirables fréquents

• Clinical Trials In clinical studies, drug related adverse events which were reported in greater than 1% of the fosfomycin-treated study population are listed below: Drug-Related Adverse Events (%) in Fosfomycin and Comparator Populations Adverse Events Fosfomycin N=1,233 Nitrofurantoin N=374 Trimethoprim/sulfamethoxazole N=428 Ciprofoxacin N=455 Diarrhea 9.0 6.4 2.3 Vaginitis 5.5 5.3 4.7 Nausea...

Grossesse

Teratogenic Effects When administered intramuscularly as the sodium salt at a dose of 1 gram to pregnant women, fosfomycin crosses the placental barrier. Fosfomycin tromethamine crosses the placental barrier of rats; it does not produce teratogenic effects in pregnant rats at dosages as high as 1,000 mg/kg/day (approximately 9 and 1.4 times the human dose based on body weight and mg/m 2, respectively).

Titulaire de l'autorisation:

Amneal Pharmaceuticals NY LLC

Version de la notice:

2 avril 2024

Les sections ci-dessus sont citées de la notice en anglais, car c'est ce document qui porte l'autorisation. Lorsqu'une autorité européenne publie les mêmes informations en français, le lien figure dans les sources. Nous ne traduisons pas nous-mêmes les textes réglementaires : une erreur de traduction dans une contre-indication serait plus dangereuse qu'une ligne en langue étrangère.

Cette section rapporte les informations produit approuvées. Le texte est condensé à partir du résumé de l'autorité elle-même, et le document complet figure dans les sources.